Scroll back to top

VistaSeq® Pancreatic Cancer Panel

CPT: 81162; 81201; 81203; 81292; 81294; 81295; 81297; 81298; 81300; 81307; 81317; 81319; 81351; 81403(x2); 81404(x3); 81405; 81408; 81479
Print Share


  • Familial Cancer testing
  • Hereditary Cancer testing
  • Inherited Cancer testing

Test Includes


Special Instructions

A hereditary cancer clinical questionnaire should be submitted with all specimens. Contact CMBP genetic services at 800-345-4363 to coordinate testing.

Expected Turnaround Time

24 - 28 days

Specimen Requirements


Whole blood or saliva collected in an Oragene Dx collection kit


10 mL whole blood, 2 mL saliva

Minimum Volume

7 mL whole blood, 0.5 mL saliva


Lavender-top (EDTA) tube or yellow-top (ACD) tube or Oragene Dx 500 saliva collection kit


Blood is collected by routine phlebotomy. Saliva is collected by spitting into the provided container until it reaches the fill line.

Storage Instructions

Room temperature

Stability Requirements



Room temperature

60 days


60 days

Causes for Rejection

Frozen specimen; leaking tube; clotted specimen; grossly or hemolyzed specimen; quantity not sufficient for analysis; incorrect anticoagulant; saliva collection in an incorrect container. Do not eat, drink, smoke, or chew gum 30 minutes prior to saliva sample collection. See Oragene Dx 500 saliva kit for detailed instructions.

Test Details


This assay is intended for patients with a family history consistent with an inherited cancer syndrome.


Sequencing cannot detect variants in regions not covered by this analysis, including noncoding or deep intronic variants and may not reliably detect changes in repetitive elements, such as microsatellite repeats. Sequencing may not detect mosaic variants, inversions, or other genomic rearrangements such as transposable element insertions. Sequence analysis may also be affected by allele drop-out due to the presence of a rare variant under a primer site or homopolymeric regions. The method does not allow any conclusion as to whether two heterozygous variants are present on the same or on different chromosome copies.

Copy number variations are assessed by microarray or multiple-ligation-probe amplification assay (MLPA) to detect gross deletions and duplications. Copy number analyses are designed to detect single exon, multi-exon, and full gene deletions or duplications. These analyses may not detect certain genomic rearrangements, such as translocations (balanced or unbalanced), inversions, or some partial exon rearrangements. This assay cannot determine exact breakpoints of deletions or duplications detected.

The presence of pseudogenes can interfere with the ability to detect variants in certain genes. For example, deletion/duplication analysis of PMS2 exons 11-15, among others, is complicated by the highly homologous PMS2CL pseudogene. Deletions/duplications in PMS2CL have not been associated with Lynch syndrome; however, this assay may not be able to determine if a deletion/duplication affects PMS2 or PMS2CL.

Each gene sequence is interpreted independently of all other gene sequences; however, variants in different genes may interact to cause or modify a typically monogenic disease phenotype.

In addition, the presence of an inherited cancer syndrome due to a different genetic cause cannot be ruled out. Any interpretation given should be clinically correlated with available information about presentation and the patient's relevant family history.

This test is not intended to detect somatic variants. Bone marrow transplantation may affect the outcome of these results. Please contact Labcorp at 1-800-345-GENE to discuss testing options.

This test was developed and its performance characteristics determined by Labcorp. It has not been cleared or approved by the Food and Drug Administration.


The coding region and flanking splice sites are analyzed by NGS (+/-10bp) and deletion/duplication analysis. Exon-level deletions/duplications are assessed by aCGH or by MLPA. Analysis is limited to deletion/duplication testing for EPCAM. Analysis is expanded for BRCA1/2 flanking splice sites (+/-20bp) and to include promoter deletions for APC (1B and 1A). Clinically significant findings are confirmed by Sanger sequencing or qPCR. Results are reported using ACMG guidelines and nomenclature recommended by the Human Genome Variation Society (HGVS).


Order Code Order Code Name Order Loinc Result Code Result Code Name UofM Result LOINC
481385 VistaSeq Pancreatic Cancer 73977-1 481397 Specimen Type 31208-2
481385 VistaSeq Pancreatic Cancer 73977-1 481398 Preauthorization N/A
481385 VistaSeq Pancreatic Cancer 73977-1 481399 Result Summary 51968-6
481385 VistaSeq Pancreatic Cancer 73977-1 481400 Result and Interpretation 69548-6
481385 VistaSeq Pancreatic Cancer 73977-1 481401 Recommendations 47042-7
481385 VistaSeq Pancreatic Cancer 73977-1 481402 Additional Information 77202-0
481385 VistaSeq Pancreatic Cancer 73977-1 481403 Methodology and Limitations 49549-9
481385 VistaSeq Pancreatic Cancer 73977-1 481404 References 75608-0
481385 VistaSeq Pancreatic Cancer 73977-1 481405 Director Review 72486-4
481385 VistaSeq Pancreatic Cancer 73977-1 481406 PDF 51969-4